Seeking Alpha

MissionIR's  Instablog

MissionIR
Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
MissionIR
My blog:
MissionIR Blog
  • Soligenix, Inc. (SNGX) Completes Phase 1 Study With SGX203, Treatment Of Pediatric Crohn's Disease 0 comments
    Jul 1, 2013 4:04 PM | about stocks: SNGX

    Soligenix, a clinical stage biopharmaceutical company developing products to treat serious gastrointestinal diseases, has enrolled and treated all 24 patients in the phase 1 Study BDP-PCD-01, the first clinical study for development of SGX203 (oral BDP) for the treatment of pediatric Crohn's disease.

    The objective of Study BDP-PCD-01 was to further characterize the pharmacokinetic (PK) and pharmacodynamic (PD) profile of the company's proprietary oral BDP formulation. Soligenix reports that the data was complementary to results previously obtained and confirms the safety profile observed in all previous clinical studies with oral BDP.

    This study enrolled subjects between the ages of 18-22. The company said preliminary PK results indicate that the PK profile in this population matches the profile established in previous studies in a broader population and supports a twice-a-day dosing regimen. SGX203 was found to be safe and well-tolerated.

    "We have designed this program in collaboration with an expert in PK modeling and simulation, Jeffrey S. Barrett, PhD, FCP, from The Children's Hospital of Philadelphia," Kevin J. Horgan, MD, senior vice president and chief medical officer of Soligenix stated in the press release. "The use of PK data in this way reflects the current state of the art in pediatric drug development, leveraging the maximum amount of information from the enrolled subjects."

    Soligenix will use the PK data generated from the study to refine the PK model the company has established with Dr. Barrett, and is expected to justify limited PK sampling in the phase 2/3 pediatric clinical study and help determine the dose selection for the phase 3 study.

    The SGX203 development program previously received Fast Track and Orphan Drug designations from the U.S. FDA for oral BDP as a treatment for pediatric Crohn's disease.

    For more information, visit www.soligenix.com

    About MissionIR

    MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

    Sign up for "The Mission Report" at www.MissionIR.com

    Please see disclaimer on the MissionIR website
    http://www.missionir.com/disclaimer.html

    Stocks: SNGX
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.